as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and apolipoprotein B (Apo B) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). • as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and adolescent girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia and the following findings are present: o LDL-C remains ? 190 mg/dL or o LDL-C remains ? 160 mg/dL and: ? there is a positive family history of premature cardiovascular disease or ? two or more other cardiovascular disease risk factors are present Secondary Prevention of Cardiovascular Disease In patients with clinically evident CHD to: • reduce the risk of undergoing coronary revascularization procedures • slow the progression of coronary atherosclerosis
Oral; 20 mg to 80 mg/ day.
Hypersensitivity to component of medicine
Paediatric: Use with caution; safety and efficacy studied in 9 to 16 year age group Pregnancy: Not to use; category X Lactation: Not to use Elderly: Use with caution.
abdominal pain, diarrhea, nausea, dyspepsia and chest pain, Rhabdomyolysis with myoglobinuria and acute renal failure and myopathy (including myositis), Liver Enzyme Abnormalities
Fluconazole, cyclosporin, gemfibrozil, niacin, glyburide, phenytoin, warfarin, colchicine